IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Aurobindo and Celon Laboratories form generics JV to cater US and Europe

9:53 AM MST | December 10, 2013 | Natasha Alperowicz

Celon Laboratories (Hyderabad, India) said on Monday that it has entered into an agreement with Aurobindo Pharma (Hyderabad) to form a joint venture to develop, manufacture, and sell hormonal and oncology generic formulations for the US and European markets. A special-purpose vehicle company, Eugia Pharma Specialties, will be formed and in which Aurobindo will hold 60% and Celon 40%. The companies will invest a combined 1.8–2.0 billion Indian rupees ($29.5–32.8 million) in the jv over the next two to three years. Aurobindo, in August, agreed to...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa